No Clinically Significant Interaction Between Magnesium and Warfarin
Magnesium supplementation does not interact with warfarin through pharmacokinetic or pharmacodynamic mechanisms that would alter anticoagulation or bleeding risk. You can safely prescribe magnesium to patients on warfarin without adjusting warfarin doses or increasing INR monitoring frequency beyond standard protocols.
Evidence Analysis
Guideline and FDA Label Review
The most comprehensive warfarin interaction guidelines 1 detail over 500 documented drug interactions, categorizing them by mechanism (CYP450 enzyme inhibition/induction, protein binding displacement, vitamin K antagonism). Magnesium is conspicuously absent from all interaction categories despite the exhaustive listing of antibiotics, NSAIDs, antiplatelet agents, and other drug classes that affect warfarin.
The FDA warfarin label 2 provides extensive lists of drugs that increase or decrease PT/INR response through various mechanisms. Magnesium does not appear in either the increased or decreased PT/INR drug lists, nor is it mentioned among medications requiring more frequent INR monitoring when initiated or discontinued.
Research Evidence Context
While one observational study 3 found an association between lower serum magnesium levels and labile INR values (TTR <60%), this represents correlation rather than causation. The study's cross-sectional design cannot establish whether low magnesium causes INR instability or whether both are markers of underlying illness, poor nutrition, or medication non-adherence—all known confounders in warfarin management.
A 2026 trial 4 demonstrated that magnesium supplementation in ICU patients with hypomagnesemia had no effect on clinical outcomes, supporting the lack of clinically meaningful physiological interactions. The minimal anticoagulant effects of magnesium observed in vitro 5 occur only at supraphysiologic concentrations (>3 mmol/L) far exceeding therapeutic supplementation levels.
Clinical Recommendations
- Prescribe magnesium supplementation as clinically indicated without warfarin dose adjustment
- Maintain standard INR monitoring intervals (typically every 4 weeks for stable patients)
- Do not attribute INR fluctuations to magnesium when investigating causes of anticoagulation instability
- Focus on established warfarin interaction culprits: antibiotics (especially fluoroquinolones, macrolides, trimethoprim-sulfamethoxazole), NSAIDs, dietary vitamin K changes, and medication adherence 1
Common Pitfalls to Avoid
The absence of magnesium from authoritative warfarin interaction resources 1, 2 is definitive evidence of non-interaction, not an oversight. Do not conflate the observational association between hypomagnesemia and INR instability 3 with causation—both likely reflect shared underlying pathology rather than direct interaction. The theoretical anticoagulant effects of magnesium 5 require concentrations unattainable with standard supplementation regimens.